Monte Rosa Therapeutics (GLUE) Earnings Analysis
Monte Rosa Therapeutics (GLUE) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it missed with EPS -0.45 USD vs -0.28 USD est (-60.7%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -12.79.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does GLUE next report earnings?
No confirmed upcoming earnings date is currently scheduled for GLUE. This page updates as the calendar is published.
GLUE earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.45 USD | -0.28 USD | -60.7% | Miss |
| 2026-03-17 | -0.54 USD | -0.35153 USD | -53.6% | Miss |
| 2025-05-08 | 0.57 USD | -0.00264 USD | +21690.9% | Beat |
| 2025-03-20 | 0.23 USD | 0.01555 USD | +1379.1% | Beat |
Beat rate: 2/4 (50%) over reported quarters with consensus data.
GLUE valuation and analyst view
| Trailing P/E | -12.79 |
|---|---|
| Trailing EPS | -1.98362 USD |
| Price / book | 2.99 |
| Dividend yield | 0.00% |
| Market cap | 1.52B |
| Analyst consensus | Buy (7 buy / 2 hold / 0 sell) |
| Avg price target | 35 USD |
Related research pages
Frequently asked questions
When is Monte Rosa Therapeutics (GLUE)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for GLUE. This page updates as the calendar is published.
Did GLUE beat earnings last quarter?
In its 2026-05-07 report, GLUE posted EPS of -0.45 USD versus a -0.28 USD estimate — a miss of 60.7%.
What is GLUE's earnings track record?
Over the last 4 reported quarters with consensus data, GLUE beat estimates 2 times (50%).
What is GLUE's current P/E ratio and EPS?
GLUE trades at a trailing P/E of -12.79 on trailing EPS of -1.9836224439066423 USD.
What do analysts rate GLUE?
Analyst consensus is "Buy" across 9 ratings (0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 35 USD.